DYRK1A inhibition as a novel treatment approach for Alzheimer's disease - Resubmission

DYRK1A inhibition as a novel treatment approach for Alzheimer's disease - Resubmission DYRK1A inhibition as a novel treatment approach for Alzheimer's disease - Resubmission Dr. Dunckley and his team will perform characterization of DYR compounds using in vitro and cell-based assays. He will also perform in vivo testing of select, optimized compounds in the 3XTg-AD mouse model and conduct behavioral and neuropathological experiments on treated and untreated cohorts.